Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver…
Biotechnology
US, Foster City [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Terns Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -1.6700 | -1.334 | 0 | 0 | -60 | -95 | -58 | 0 | -63 | 0 | 22 | 0 |
| 2024 | -1.2700 | -1.191 | 0 | 1 | -90 | -84 | -102 | 1 | -103 | 1 | 39 | 9 |
| 2025 | - | -1.318 | - | 1 | - | -91 | - | 1 | - | 1 | - | 8 |
| 2026 | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2027 | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2028 | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |